Akebia Therapeutics' Series B - II Round

Akebia Therapeutics raised a round of funding on January 09, 2012.

Akebia Therapeutics is focused on discovering and developing therapeutic solutions leveraging the potential of the hypoxia-inducible factor - or HIF - biology. HIF-Prolyl Hydroxylase inhibition could…

Articles about Akebia Therapeutics' Series B - II Round: